MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/bloodadvances.2023011920

Медицинская библиотека · Blood advances · 2024

MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial.

Jerkeman Mats, Kolstad Arne, Hutchings Martin, Pasanen Annika, Meriranta Leo, Niemann Carsten Utoft, Kragh Jørgensen Rasmus Rask, El-Galaly Tarec Christoffer, Riise Jon, Leppä Sirpa, Christensen Jacob Haaber, Sonnevi Kristina, Pedersen Lone Bredo, Wader Karin Fahl, Glimelius Ingrid

Многоцентровое исследованиеКлиническое исследование II фазыКлиническое исследование I фазыСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Despite improvements in treatment of mantle cell lymphoma (MCL), most patients eventually relapse. In this multicenter phase 1b/2 trial, we evaluated safety and efficacy of minimal residual disease (MRD)-driven venetoclax, lenalidomide, and rituximab (venetoclax-R2) in relapsed/refractory (R/R) MCL and explored the feasibility of stopping treatment in molecular remission. The primary end point was overall response rate (ORR) at 6 months. After dose escalation, the recommended phase 2 dose was lenalidomide 20 mg daily, days 1 to 21; venetoclax 600 mg daily after ramp-up; and rituximab 375 mg/m2 weekly for 4 weeks, then every 8 weeks. MRD monitoring by RQ-PCR was performed every 3 months. When MRD-negativity in the blood was reached, treatment was continued for another 3 months; if MRD-negativity was then confirmed, treatment was stopped. In total, 59 patients were enrolled, with a median age of 73 years. At 6 months, the ORR was 63% (29 complete remission [CR], 8 partial remission [PR]), and 40% (4 CR, 2 PR) for patients previously failing a Bruton tyrosine kinase (BTK) inhibitor. Median progression-free survival (PFS) was 21 months, with median overall survival of 31 months. TP53 mutation was associated with inferior PFS (P < .01). Overall, 28 patients (48%) discontinued treatment in molecular remission, and 25 remain MRD negative after a median of 17.4 months. Hematological toxicity was frequent, with 52 of 59 (88%) patients with G3-4 neutropenia and 21 of 59 (36%) patients with G3-4 thrombocytopenia. To conclude, MRD-driven venetoclax-R2 is feasible and tolerable and shows efficacy in R/R MCL, also after BTK inhibitor failure. This trial was registered at www.ClinicalTrials.gov as #NCT03505944.

Для цитирования: Jerkeman Mats, Kolstad Arne, Hutchings Martin, Pasanen Annika, Meriranta Leo, Niemann Carsten Utoft, Kragh Jørgensen Rasmus Rask, El-Galaly Tarec Christoffer, Riise Jon, Leppä Sirpa, Christensen Jacob Haaber, Sonnevi Kristina, Pedersen Lone Bredo, Wader Karin Fahl, Glimelius Ingrid. MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial.. Blood advances. 2024. DOI: 10.1182/bloodadvances.2023011920.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.